Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Endogenous opioids and µ-opioid receptors have been linked to hedonic and rewarding aspects of palatable food intake. The authors examined the safety, pharmacokinetic, and pharmacodynamic profile of GSK1521498, a µ-opioid receptor inverse agonist that is being investigated primarily for the treatment of overeating behavior in obesity. In healthy participants, GSK1521498 oral solution and capsule formulations were well tolerated up to a dose of 100 mg. After single doses (10-150 mg), the maximum concentration (C(max)) and area under the curve (AUC) in plasma increased in a dose-proportional manner. GSK1521498 selectively reduced sensory hedonic ratings of high-sugar and high-fat dairy products and caloric intake of high-fat/high-sucrose snack foods. These findings provide encouraging data in support of the development of GSK1521498 for the treatment of disorders of maladaptive ingestive behavior or compulsive consumption.

Original publication

DOI

10.1177/0091270011399577

Type

Journal article

Journal

J clin pharmacol

Publication Date

04/2012

Volume

52

Pages

464 - 474

Keywords

Administration, Oral, Adult, Area Under Curve, Cross-Over Studies, Dose-Response Relationship, Drug, Double-Blind Method, Drug Inverse Agonism, Eating, Food Preferences, Humans, Indans, Male, Receptors, Opioid, mu, Single-Blind Method, Triazoles